Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: A possible alternative for primary screening of nasopharyngeal carcinoma

Oral Oncology

Volumn 44, Issue 8, 2008, Pages 784-792

  Chang, Kai Ping ^a,b   Hsu, Cheng Lung ^a   Chang, Yu Liang ^a   Tsang, Ngan Ming ^a   Chen, Chin Kuo ^a   Lee, Ta Jen ^a   Tsao, Kuo Chien ^a   Huang, Chung Guei ^a   Chang, Yu Sun ^b   Yu, Jau Song ^b   Hao, Sheng Po ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Early antigen; Epstein Barr virus; Head and neck; Nasopharyngeal carcinoma; Nuclear antigen 1

Indexed keywords

CELL NUCLEUS ANTIGEN; EARLY ANTIGEN; IMMUNOGLOBULIN A; VIRUS ANTIBODY; VIRUS CAPSID ANTIGEN;

ADULT; ANTIBODY TITER; ARTICLE; CANCER RELAPSE; CANCER SCREENING; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIRUS LOAD;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HUMANS; IMMUNOGLOBULIN A; MALE; MASS SCREENING; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR VIRUS INFECTIONS;

EID: 47249104308     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2007.10.003     Document Type: Article

References (25)

1. Lin J.C., Jan J.S., Hsu C.Y., Liang W.M., Jiang R.S., and Wang W.Y. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21 4 (2003) 631-637
2. Cheng S.H., Jian J.J., Tsai S.Y., Yen K.L., Chu N.M., Chan K.Y., et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 48 5 (2000) 1323-1330
3. Lee A.W., Sze W.M., Au J.S., Leung S.F., Leung T.W., Chua D.T., et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61 4 (2005) 1107-1116
4. Chang K.P., Hao S.P., Lin S.Y., Ueng S.H., Pai P.C., Tseng C.K., et al. The 30-bp deletion of Epstein-Barr virus latent membrane protein-1 gene has no effect in nasopharyngeal carcinoma. Laryngoscope 116 4 (2006) 541-546
5. Ho H.C., Ng M.H., Kwan H.C., and Chau J.C. Epstein-Barr-virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br J Cancer 34 6 (1976) 655-660
6. Henle G., and Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 17 1 (1976) 1-7
7. de-Vathaire F., Sancho-Garnier H., de-The H., Pieddeloup C., Schwaab G., Ho J.H., et al. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multicenter follow-up study. Int J Cancer 42 2 (1988) 176-181
8. Nadala E.C., Tan T.M., Wong H.M., and Ting R.C. ELISA for the detection of serum and saliva IgA against the BMRFI gene product of Epstein-Barr virus. J Med Virol 50 1 (1996) 93-96
9. Cheng H.M., Foong Y.T., Sam C.K., Prasad U., and Dillner J. Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors. J Clin Microbiol 29 10 (1991) 2180-2186
10. Yip T.T., Ngan R.K., Lau W.H., Poon Y.F., Joab I., Cochet C., et al. A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer 74 9 (1994) 2414-2424
11. Lo Y.M., Chan L.Y., Lo K.W., Leung S.F., Zhang J., Chan A.T., et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 59 6 (1999) 1188-1191
12. Lin J.C., Wang W.Y., Chen K.Y., Wei Y.H., Liang W.M., Jan J.S., et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350 24 (2004) 2461-2470
13. Fan H., Nicholls J., Chua D., Chan K.H., Sham J., Lee S., et al. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer 112 6 (2004) 1036-1041
14. Chow K.C., Ma J., Lin L.S., Chi K.H., Yen S.H., Liu S.M., et al. Serum responses to the combination of Epstein-Barr virus antigens from both latent and acute phases in nasopharyngeal carcinoma: complementary test of EBNA-1 with EA-D. Cancer Epidem Biomar Prev 6 5 (1997) 363-368
15. Hsu M.M., Hsu W.C., Sheen T.S., and Kao C.L. Specific IgA antibodies to recombinant early and nuclear antigens of Epstein-Barr virus in nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci 26 4 (2001) 334-338
16. O'Sullivan B., and Shah J. New TNM staging criteria for head and neck tumors. Semin Surg Oncol 21 1 (2003) 30-42
17. Chang Y.S., Tyan Y.S., Liu S.T., Tsai M.S., and Pao C.C. Detection of Epstein-Barr virus DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA amplification. J Clin Microbiol 28 11 (1990) 2398-2402
18. Chen C.L., Wen W.N., Chen J.Y., Hsu M.M., and Hsu H.C. Detection of Epstein-Barr virus genome in nasopharyngeal carcinoma by in situ DNA hybridization. Intervirology 36 2 (1993) 91-98
19. Wu T.C., Mann R.B., Epstein J.I., MacMahon E., Lee W.A., Charache P., et al. Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J Pathol 138 6 (1991) 1461-1469
20. Raab-Traub N., and Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47 6 (1986) 883-889
21. Levine P.H., Pearson G.R., Armstrong M., Bengali Z., Berenberg J., Easton J., et al. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC). Cancer Detect Prev 4 1-4 (1981) 307-312
22. Hsiao J.R., Jin Y.T., and Tsai S.T. Detection of cell free Epstein-Barr virus DNA in sera from patients with nasopharyngeal carcinoma. Cancer 94 3 (2002) 723-729
23. Chan K.H., Gu Y.L., Ng F., Ng P.S., Seto W.H., Sham J.S., et al. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer 105 5 (2003) 706-709
24. Lo Y.M., Chan L.Y., Chan A.T., Leung S.F., Lo K.W., Zhang J., et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 59 21 (1999) 5452-5455
25. Wei W.I., Sham J.S., Zong Y.S., Choy D., and Ng M.H. The efficacy of fiberoptic endoscopic examination and biopsy in the detection of early nasopharyngeal carcinoma. Cancer 67 12 (1991) 3127-3130